Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of QVA149 vs QAB149 in Moderate to Severe COPD (FLIGHT 3)
NCT01682863Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Oct 2012; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01682863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682863.